Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics (Nasdaq: BNGO) reported Day 2 highlights from Symposium 2026 focused on oncology and bioprocessing applications of Optical Genome Mapping (OGM). Presentations showed OGM detecting complex structural variants in multiple myeloma, rare sarcomas, and engineered cell lines, and discussed FDA and ISSCR recognition for genome-integrity analysis.
Attendance exceeded 1,150 registrants from 73 countries; session recordings will be available on Bionano's YouTube channel.
Bionano Genomics (Nasdaq: BNGO) reported Day 1 highlights from Symposium 2026 focused on optical genome mapping (OGM) for hematologic malignancies. Nine presentations showed OGM's high concordance with traditional cytogenetics and its ability to resolve complex structural variants, integrate with NGS via VIA, and rescue failed assays.
More than 1,000 attendees from 70 countries participated; session recordings will be available on the company YouTube channel, with the live panel Q&A excluded from on-demand.
Bionano (Nasdaq: BNGO) announced Bionano Symposium 2026, a free virtual event Feb 23-26, 2026 showcasing optical genome mapping (OGM) research and applications.
The four-day program features >30 international researchers, sessions on oncology, hematologic malignancies, constitutional genetics, bioprocessing, and demonstrations of Ionic, Saphyr, Stratys, and VIA.
Bionano Genomics (Nasdaq: BNGO) highlighted a peer-reviewed study showing optical genome mapping (OGM) can detect genomic alterations introduced by gene editing methods in human iPSC lines. The study reports OGM sensitivity to variant allele fractions as low as 5%, found variable transgene insertion counts by technology, and identified complex structural variants missed by traditional methods.
Findings suggest OGM may serve as a complementary QC tool to assess genome integrity and reveal potentially pathogenic off-target rearrangements in engineered cell lines used for therapeutic development.
Bionano Genomics (NASDAQ: BNGO) reported preliminary unaudited results for Q4 and full-year 2025. Q4 revenue is expected to be $7.8M–$8.0M (down ~2%–4% YoY) and FY2025 revenue is expected to be $28.4M–$28.6M (down ~7%–8% YoY). Nanochannel array flowcells sold: 7,554 in Q4 and 30,171 for FY2025. Installations: 9 systems in Q4 and 32 systems in FY2025, with a year-end installed base of 387 systems (vs. 371 at 2024 year-end). Cash and equivalents totaled ~$29.6M (with $10.3M restricted). Results are preliminary and subject to change after year-end close and audit.
Bionano Genomics (NASDAQ: BNGO) recapped advances in optical genome mapping (OGM) showcased at the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston.
Thirteen studies presented OGM results across inherited disease, reproductive disorders, hematologic malignancies, and solid tumors, highlighting improved detection of structural variants (SVs), novel clinically relevant findings, and integration with cytogenetics and next-generation sequencing (NGS). Presentations also reported streamlined lab workflows and OGM application to fresh-frozen and FFPE samples using Bionano workflows and kits.
Bionano Laboratories (Nasdaq: BNGO) announced that the 2026 Clinical Lab Fee Schedule posted by CMS increases the Category I CPT code 81195 payment by 47%, from $1,263.53 to $1,853.22, effective January 1, 2026.
The CDLT committee voted 10-0 in favor of the proposed crosswalk that supported the higher payment; CMS adopted the panel recommendation. CPT code 81195 covers OGM use in cytogenomic analysis for hematologic malignancies. Bionano said the new payment level should aid reimbursement for its OGM-based LDTs such as OGM-Dx HemeOne.
Bionano Genomics (Nasdaq: BNGO) reported Q3 2025 results on November 13, 2025, with total revenue of $7.4M, up 21% year-over-year from $6.1M.
Key metrics: consumables and software revenue +15%, sold 8,390 flowcells (+7% YoY), installed base 384 systems (+4% YoY), and gross margin 46% (non-GAAP 46%). Operating expenses were reduced to $11.9M (GAAP) and non-GAAP operating expense was $9.7M. Cash and equivalents totaled $31.8M. The company raised $10M in a September public offering and reiterated FY2025 revenue guidance of $26.0–$30.0M.
Bionano (Nasdaq: BNGO) announced a peer-reviewed MD Anderson study published in Cancers showing optical genome mapping (OGM) can overcome key limitations of targeted RNA-seq for detecting gene rearrangements in acute leukemia.
In a cohort of 467 subjects, 234 gene rearrangements/fusions were detected across 206 subjects (43.6%). OGM and RNA-seq both detected 175 events (74.7% of positives); OGM uniquely found 37 events (15.8%) and RNA-seq uniquely found 22 (9.4%). Tier 1 aberrations appeared in 147 subjects (31.5%). RNA-seq detected only 20.6% of enhancer-hijacking events found by OGM. The study concludes OGM plus RNA-seq yields the most comprehensive genomic profiling in acute leukemia.
Bionano Genomics (Nasdaq: BNGO) will report its third quarter 2025 financial results and host a conference call and live webcast on Thursday, November 13, 2025 at 4:30 p.m. ET.
Investors can join via the live webcast at https://edge.media-server.com/mmc/p/4jh5a49o or register through the participant link; a replay will be archived on the company investor relations site for at least 30 days.
Company and investor relations contacts are provided for follow-up inquiries.